The study suggests treating babies who have neonatal abstinence syndrome (NAS) with buprenorphine could cut treatment time nearly in half, from an average of 28 days to 15 days.
Walter K. Kraft, M.D., first author of the Jefferson study, told McCullough, “This is a practice-changing advance for treatment of babies with NAS. We predict that buprenorphine will become the new standard of care.” Kraft added that in addition to its shortening treatment time, “Buprenorphine may have a built-in safety effect. Giving more of the drug won’t lead to a corresponding increase in toxicity.”
The Wall Street Journal, Science Magazine, Reuters and additional news media reported on the study.